Adimmune Corporation (4142.TW)
Taiwan · TWD · Healthcare · Biotechnology
NT$17.55 (-1.40%) as of
Key statistics
- Market cap
- 7.40B
- Forward P/E
- 146.25
- EPS (TTM)
- -0.34
- Dividend yield
- 0.00%
- 52-week range
- 16.40 – 22.50
- Beta
- 0.27
- Revenue (TTM)
- 1.37B
- Profit margin
- -10.48%
- Analyst target
- NT$21.00
- Volume
- 570.79k
About Adimmune Corporation
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taichung, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.